REG - GSK PLC - Shingrix data demonstrate 100% efficacy in China

GSKAnnouncement

23/08/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230823:nRSW1243Ka&default-theme=true

RNS Number : 1243K  GSK PLC  23 August 2023

Issued: 23 August 2023, London UK

 

New Shingrix data demonstrate 100% vaccine efficacy in the prevention of
shingles in adults aged 50 and over in China

 

·   No cases of shingles (herpes zoster) reported among the participants
who received Shingrix (Recombinant Zoster Vaccine or RZV) in the randomised
clinical trial 1 

·   The data come from the first efficacy trial of Shingrix in China

·   The trial's safety and efficacy data were consistent with GSK's pivotal
phase III trials ZOE-50 and ZOE-70(1)

 

 

GSK plc (LSE/NYSE: GSK) today announced positive results from the first-ever
efficacy trial of Shingrix (Recombinant Zoster Vaccine or RZV) in China. These
results come from the post-license phase IV trial (ZOSTER-076), which
evaluated the efficacy and safety of RZV in preventing shingles in adults aged
50 and over. The trial included almost 6,000 participants randomised 1:1 to
the RZV or placebo group and followed in an observer-blind design. No cases of
shingles were reported among the participants who received RZV, compared to 31
cases in the placebo arm.(1)

 

The results are in line with findings from the pivotal phase III trials ZOE-50
and ZOE-70 investigating the efficacy and safety of RZV, showing vaccine
efficacy was up to 97% 2  in adults aged 50 and over, over a follow-up period
of approximately four years.(2)(,) 3  The safety profile observed in this
trial was consistent with the established safety profile of the vaccine.(1)
The new data add to the growing body of evidence affirming the efficacy and
safety profile of RZV in preventing shingles in adults aged 50 and over.(1)

 

Globally, the varicella zoster virus (VZV) is present in over 90% of
adults. 4 (, 5 ) VZV remains dormant in the nervous system, waiting to
reactivate as shingles with advancing age.(8)(,)(9) The population of people
aged 65 and over in China is rapidly increasing, with a predicted percentage
increase from 6.8% in 2000 to 23.6% by 2050. 6  It is estimated that there are
approximately 6 million cases of shingles in China each year(6), and this
number is expected to increase in line with local population ageing.

 

RZV was first licensed for use in China in 2019 for the prevention of herpes
zoster in adults aged 50 and over. This post-licence trial was undertaken to
fulfil the requirement of regulatory authorities to evaluate the vaccine
efficacy and safety of two doses of RZV for the prevention of shingles in
China. The trial further demonstrates RZV's efficacy in preventing herpes
zoster in adults aged 50 and over irrespective of sex, geographic region and
ancestry/ethnicity.

 

Results from this phase IV trial will be submitted for publication in a
peer-reviewed scientific journal later this year.

 

About the ZOSTER-076 trial

ZOSTER-076 was a phase IV, randomised, observer-blind, placebo-controlled,
multi-centre trial to assess the prophylactic efficacy against herpes zoster
(HZ) and the immunogenicity and safety of RZV when administered
intramuscularly on a 2-dose schedule in adults aged 50 and over in China.(1)

 

The trial was conducted between 2021 and 2023. It included almost 6,000 adults
(n=5,956). Vaccine efficacy was 100% (95% CI: 89.82%-100%). HZ incidence rate
of 0/1,000 person years in the RZV arm versus an incidence rate of 8.2/1,000
person years in the placebo arm, p<0.0001.(1) The safety profile observed
in this trial was consistent with the established safety profile of the
vaccine.(1)

 

About shingles

Shingles, also known as herpes zoster, is caused by a reactivation of the
varicella-zoster virus (VZV) - the same virus that causes chickenpox. 7 
(#_edn7) Globally, most people aged 50 and over have the dormant VZV in their
nervous system and are at risk of developing shingles.(4)(,)(5) As people age,
the strength of the immune system wanes, leading to a decreased response to
infection and thus increasing the risk of developing
shingles.(4,)(5)(,7, 8 , 9 ) People with

a suppressed or compromised immune system are also at risk of shingles. 10 

 

Shingles typically presents as a rash, with painful blisters across the chest,
abdomen or face.(7) The pain is often described as aching, burning, stabbing
or shock-like.(9) Following the rash, a person can also experience
post-herpetic neuralgia (PHN), a long-lasting nerve pain that can continue for
weeks or months and in some cases can persists for several years.(9) PHN is
the most common complication of shingles, occurring in 5-30% of all shingles
cases depending on the individual's age. 11 

 

About Shingrix

Shingrix (Recombinant Zoster Vaccine or RZV) is a non-live, recombinant
subunit vaccine indicated for the prevention of shingles in adults 50 and
over. It combines an antigen, glycoprotein E, with an adjuvant system,
AS01(B), and may help overcome the natural age-related decline in responses to
immunisation that contributes to the challenge of protecting adults aged 50
and over from shingles. 12 (, 13 ) RZV is not indicated to prevent primary
varicella infection (chickenpox). In some countries, RZV is also approved for
adults aged 18 years or over who are at increased risk for shingles.

 

Please refer to the Product Information (PI) for important dosage,
administration and safety information in China available at this link:
https://portaldev2.igskapp.com/media/916483/欣安立适说明书.pdf

 

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology,
and talent to get ahead of disease together. Find out more at gsk.com.

 

 

 GSK enquiries
 Media:               Tim Foley          +44 (0) 20 8047 5502  (London)
                      Simon Moore        +44 (0) 20 8047 5502  (London)
                      Kathleen Quinn     +1 202 603 5003       (Washington DC)
                      Alison Hunt        +1 540 742 3391       (Washington DC)

 Investor Relations:  Nick Stone         +44 (0) 7717 618834   (London)
                      James Dodwell      +44 (0) 20 8047 2406  (London)
                      Mick Readey        +44 (0) 7990 339653   (London)
                      Josh Williams      +44 (0) 7385 415719   (London)
                      Camilla Campbell   +44 (0) 7803 050238   (London)
                      Steph Mountifield  +44 (0) 7796 707505   (London)
                      Jeff McLaughlin    +1 215 751 7002       (Philadelphia)
                      Frannie DeFranco   +1 215 751 4855       (Philadelphia)

 

Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to risks and
uncertainties that may cause actual results to differ materially from those
projected. Such factors include, but are not limited to, those described under
Item 3.D 'Risk factors" in the company's Annual Report on Form 20-F for 2022,
and Q2 Results for 2023 and any impacts of the COVID-19 pandemic.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

 

References

 1  GSK data on file.

 2  Lal H et al. Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in
Older Adults. N Engl J Med. 2015;372:2087-96.

 3  Cunningham AL, Lal H, Kovac M, et al. Efficacy of the Herpes Zoster
Subunit Vaccine in Adults 70 Years of Age or Older. N Engl J Med.
2016;375(11):1019-1032. doi:10.1056/NEJMoa1603800

 4  Bollaerts K et al. A systematic review of varicella seroprevalence in
European countries before universal childhood immunization: deriving incidence
from seroprevalence data. Epidemiol Infect 2017;145:2666-2677.

 5  Bricout H et al. Herpes zoster-associated mortality in Europe: a
systematic review. BMC Public Health 2015;15:466.

 6  Zhang (https://pubmed.ncbi.nlm.nih.gov/?term=Zhang%20Z%5BAuthor%5D) Z et
al. The incidence of herpes zoster in China: A meta-analysis and evidence
quality assessment. Hum Vaccin Immunother. 2023;19(2):2228169.

 7  Mueller, NH et al. Varicella Zoster Virus Infection: Clinical Features,
Molecular Pathogenesis of Disease and Latency. Neurologic Clinics, 2008;
26;675-697

(( 8 )) Johnson RW et al. Herpes zoster epidemiology, management, and disease
and economic burden in Europe: a multidisciplinary perspective. Therapeutic
Advances in Vaccines. 2015;3(4):109-120.

(( 9 )) Harpaz R et al. Advisory Committee on Immunization Practices (ACIP),
Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster:
recommendations of the Advisory Committee on Immunization Practices (ACIP).
MMWR Recomm Rep. 2008;57(RR-5):1-30.

 10  Huang C-T et al. Association Between Diabetes Mellitus and the Risk of
Herpes Zoster: A Systematic Review and Meta-analysis. J Clin Endocrinol Metab
2022;107:586-597.

 11  Kawai K, Gebremeskel BG, Acosta CJSystematic review of incidence and
complications of herpes zoster: towards a global perspectiveBMJ Open
2014;4:e004833. doi: 10.1136/bmjopen-2014-004833

 12  Cunningham et al. Vaccine profile of herpes zoster (HZ/su) subunit
vaccine. Expert Review of Vaccines. 2017;16:7;661-670.

 13  The GSK proprietary AS01 adjuvant system contains QS-21 Stimulon®
adjuvant licensed from Antigenics LLC, a wholly owned subsidiary of Agenus
Inc. (NASDAQ: AGEN), MPL and liposomes.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCQLLFLXVLBBBV